Who
Olivier Brandicourt
Director
Company insider
Files Form 4 as: Director, Vaxcyte; Director, BeOne Medicines; Director, Alnylam Pharmaceuticals; Business Unit President, Pfizer.
In numbers
- Trades disclosed
- 112
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $3.2M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 31 Dec 2010
- Last trade
- 15 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 16 Jun 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code A | —2,194 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,034 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,034 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code A | —2,194 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —18,980 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —18,980 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —671 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,441 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,441 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —671 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code A | —1,357 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,750 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,750 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code A | —1,357 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,807 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code A | —1,148 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,750 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —10,985 at $0.00 | filing |
| 8 May 2025filed 12 May 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,558 at $0.00 | filing |
| 8 May 2025filed 12 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —775 at $0.00 | filing |
News
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and PfizerPFE · fool.com · 23 Oct 2026Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in RevenuePFE · aol.com · 22 Oct 2026Appeals Court Throws Out Alex Berenson's Case Against Pfizer ExecutivesPFE · theepochtimes.com · 22 Oct 2026
0 headlines in the last 90 days name Olivier Brandicourt; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.